Brexanolone Production Cost Reports

The report provides a detailed analysis essential for establishing a brexanolone production plant. It encompasses all critical aspects necessary for brexanolone production, including the cost of brexanolone production, brexanolone plant cost, brexanolone production costs, and the overall brexanolone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a brexanolone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Brexanolone is a neuroactive steroid drug that is mainly used in the pharmaceutical and healthcare sectors. It is primarily utilised for the treatment of postpartum depression (PPD), which is a serious mood disorder that can occur after childbirth. It works by affecting certain receptors in the brain that help regulate mood and emotional responses, thereby reducing symptoms such as severe sadness, anxiety, and mood swings. It is usually administered through intravenous infusion in controlled medical settings to provide rapid relief from depressive symptoms. It is often used when standard oral antidepressants are not suitable or have not provided adequate relief. It is also used in specialised hospital treatments where continuous monitoring is required during therapy. In addition, it is also used in neurological research related to mood disorders and hormone-related mental health conditions, supporting the development of new therapies for depression and other psychiatric disorders.

The market for brexanolone is primarily driven by its application as a prescription medication for the treatment of mood disorders in new mothers, which promotes its demand in the pharmaceutical industry. Its application as a neurosteroid drug for the treatment of postpartum depression (PPD) in women after childbirth significantly boosts its demand in the medical and pharmaceutical industries. Its usage in supporting recovery and improving overall mental well-being in new mothers experiencing postpartum depression also drives its demand in the medical and healthcare sectors. Its application as an FDA-approved IV infusion drug in hospital settings to treat moderate-to-severe PPD unresponsive to other treatments also strengthens its market demand.

Moreover, its demand in psychiatric research for understanding neurosteroid pathways in mental health conditions, including those linked to hormonal shifts, also supports its market growth. Technological advancements in formulation and infusion delivery, supplier reliability, sustainable production practices, and efficient distribution networks also play an important role in shaping global industrial brexanolone procurement. Additionally, procurement decisions also depend on factors such as the availability and cost of raw materials, adherence to regulatory requirements, and quality control standards.

Raw Material for Brexanolone Production

According to the brexanolone production plant project report, the major raw materials for brexanolone production include pregnenolone and trifluoroacetic acid.

Production Process of Brexanolone

The extensive brexanolone production cost report consists of the following industrial production process:

1. Production via Catalytic Hydrogenation: The production process of brexanolone begins with catalytic hydrogenation of pregnenolone to produce isopregnanolone, which is an epimeric intermediate. Then, this intermediate undergoes stereoinversion at the 3β-hydroxy position using a Mitsunobu reaction, where it is treated with trifluoroacetic acid in the presence of diethyl azodicarboxylate and triphenylphosphine. The reaction leads to the formation of the corresponding trifluoroacetate with inverted configuration. During this step, triphenylphosphine oxide, formed as a byproduct, is removed by precipitation and filtration, which allows the product to be obtained in high purity after recrystallisation without chromatographic purification. Further, the trifluoroacetate intermediate is hydrolysed through saponification, followed by recrystallisation to obtain purified brexanolone as the finished product.

Brexanolone is also known by its chemical name allopregnanolone. It is a naturally occurring pregnane neurosteroid and a synthetic analogue of progesterone metabolite. It appears as a white crystalline solid and is practically insoluble in water, but it dissolves in organic solvents such as chloroform at concentrations of approximately 20 mg/mL. The molecular formula of the compound is C21H34O2, and its molar mass is 318.49 g/mol. The compound has a melting point of 176–178 degrees Celsius and its boiling point is approximately 431.2 degrees Celsius. The density of the compound is around 1.053 g/cm³. It acts as a positive allosteric modulator of GABAA receptors, functioning at both synaptic and extrasynaptic sites, and is administered as an intravenous infusion. It should be handled in a well-ventilated area, with protective clothing worn to avoid contact with skin and eyes. The compound should be stored in a tightly closed container in a cool, dry, and well-ventilated place, away from incompatible materials and foodstuff containers.